INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES

(Deemed-to-be-University) (An Autonomous Organisation of Ministry of Health and Family Welfare, Govt. of India) B. S. Devashi Marg (Govandi Station Road), Deonar, Mumbai, Maharashtra 400088 <u>https://www.iipsindia.ac.in/</u>

Serial No of IIPS-IRB Management Office:_____

International Institute for Population Sciences -Institutional Review Board (IIPS-IRB) Application form for the review of the proposal

General instructions:

a)To be filled by the Principal Investigator (PI); b) Please tick mark the appropriate one, mark NA if not applicable; and c)Attach a separate sheet if required

Title of the Proposal:

.....

Name of the Applicant Name of the Principal Investig Designation:	gator	
Department:		
Date of submission		
Type of review	_	_
Exemption from Review 🔲	Expedited Review . 🔲	Full Committee Review 🗖
Status of Review:	New 🗖	Revised

SECTION A: ADMINISTRATIVE INFORMATION						
Name, Qualifications and	Department and	Roles and	Signat			
Designation	Organization Address and	responsibilities	ure			
	contact details					
	Name, Qualifications and	Name, Qualifications and DesignationDepartment and Organization Address and	Name, Qualifications and DesignationDepartment and Organization Address and responsibilities			

SECTION A: ADMINISTRATIVE INFORMATION						
Project	Name, Qualifications and	Department and	Roles and	Signat		
Investi Designation Organization Address and responsibilities ure						
gators contact details						
Please attach a brief bio and CV for all investigators (PIs and Co-PIs) involved in the study (with						
subject s	subject specific publications limited to the previous 5 years).					

Funding Details

Project Duration:
Total Budget:
Share of the sponsor/s in total budget
Sponsor Information:
1. Indian a) Government 🔲 i.Central 🔲 ii.State 🔲 iii. Institutional 🗖
b) Private 🔲 i.Industry 🗖 ii.Development agency 🔲 iii. Self-sponsored 🗖
2. International Government Private UN agencies Other
3. Industry National Multinational
Specify the funding agency
Contact Address of Sponsor:

SECTION B: RESEARCH RELATED INFORMATION

1. Brief description of the study –background, research question aim(s) & objectives, methodology describing the potential risks & benefits, monitoring and auditing, outcome measures, statistical analysis and implication of the research findings (maximum 500 words):

2. Objectives of the study

1. Type of Study:

Socio-Behavioural Science Clinical Single center Clinical Multi- centeric Epidemiological and Public health Basic science Biological sample		Retrospective Prospective Quantitative Qualitative Mixed method	Cross sectional Longitudebnal/c Case control Systematic revie Baseline Endline Formative	
3. Clinical Trials:	_			
Drug /Vaccines/Device/Herbal 1	Reme	dies:		
i. Does the study involu- Dru		of: Devices	Vaccines	
Indian Systems of Medicin Alternate System of Medici	ne 🛙	Any other	NA	
ii. Is it approved and ma In Inc		d JUK & Europe 🗖	USA 🗖	
	Other	countries, specify 🗖		
iii. Does it involve a change	in use	, dosage, route of	Yes	No
administration?				
If yes, whether DCGI's /Any	y othe	r Regulatory authority's	Yes	No
Permission is obtained?				
If yes, Date of permission : iv. Is it an Investigational N		יייער.	Yes	No
If yes, IND No:		ug:	105	110
a). Investigator's Brochure s	ubmit	ted	Yes	No
b). <i>In vitro</i> studies data			Yes	No
c). Preclinical Studies done			Yes	No
d). Clinical Study is : Phase		Phase II 🗖 Phase III	Phase IV	1
4. Are you aware if this study	/simi	ar study is being done	elsewhere?	Yes No
If Yes, provide details				
SECTION C: PA	RTI	CIPANT RELATED IN	FORMATION	

5.	Subject	selection:
	i.	Numbe

Number of Subjects: Sampling design and Sample Size

The rationale for the selection of sample six in 100 words. In case of qualitative study describe	e
the number and type of respondents.	

Duration of fieldwork :			
Will subjects from both sexes be	recru	ited Yes	No
Please provide the inclusion and exclusion criteria of respondents	of the selection	on	
Type of subjects Volunteers	Patients		
Vulnerable subjects		Yes	No 🗖
If Vulnerable subjects, Tick the appropriate boxes			1
Pregnant WomenChildrenFetusIlliterateTerminally illSeriously illeconomically & socially backward	Mentally ch	allenged	
Special group subjects		Yes 🗖	No 🗖
If yes in special subject group, tick the appropriate Captives Institutionalized Students Any Other Staff	boxes) Employees Armed Forces		
	Will subjects from both sexes be Please provide the inclusion and exclusion criteria of respondents Type of subjects Vulnerable subjects If Vulnerable subjects, Tick the appropriate boxes Pregnant Women Children Fetus Illiterate Special group subjects If yes in special subject group, tick the appropriate Captives Students	Will subjects from both sexes be recru Please provide the inclusion and exclusion criteria of the selection of respondents Please provide the inclusion and exclusion criteria of the selection of respondents Type of subjects Volunteers Patients Vulnerable subjects Pregnant Women Children Elderly Fetus Illiterate Handicappe Terminally ill Seriously ill Mentally ch Special group subjects Institutionalized Employees If yes in special subject group, tick the appropriate boxes Employees	Will subjects from both sexes be recruited Yes Please provide the inclusion and exclusion criteria of the selection of respondents Yes Yes Type of subjects Volunteers Patients Yes Vulnerable subjects Volunteers Yes Yes If Vulnerable subjects, Tick the appropriate boxes Pregnant Women Children Elderly Fetus Illiterate Handicapped Terminally ill Seriously ill Mentally challenged Any other (Specify) Special group subjects Yes If yes in special subject group, tick the appropriate boxes) Yes Captives Institutionalized Employees

6. Privacy and confidentiality i. Study involves -	Direct Identifiers Indirect Identifiers/	coded		
	Completely anonyn			
ii. Confidential handling of da	ta by staff	Yes	No	NA
7. Use of biological/ hazardous materia i. Use of fetal tissue or abortus	lls	Yes	No	NA
ii. Use of organs or body	y fluids	Yes	No	NA
iii. Use of recombinant/ge	ene therapy	Yes	No	NA
If yes, has Department of Biotechnology DNA products been obtained?	(DBT) approval for	Yes	No	NA
iv. Use of pre-existing/s samples	tored/left over	Yes	No	NA
v. Collection for banking research	g/future	Yes	No	NA
vi. Use of ionising radiation/ra If yes, has Bhaba Atomic Researc approval for Radioactive Isotopes been obta	h Centre (BARC)	Yes	No	NA
vii. Use of Infectious/biohaza	rdous specimens	Yes	No	NA
viii. Proper disposal of materia	ıl	Yes	No	NA
ix. Will any sample collected f sent abroad?	from the patients be	Yes	No	NA
If Yes, justify with details of collaborat	tors:		1	
a) Is the proposal being sub Ministry's Screening Co collaboration?			Yes	No

b) Sample will be sent abroad because (Tick appropriate box):
Facility not available in India
Informed Consent
Are you seeking waiver of consent? If yes, please specify reasons and skip to item no. 8 Yes 🛛 🔲 No 🔲
Type of consent planned
*Written/Signed 🔲 Oral/Verbal 🔲 Audio-visual
In case of a minor children
Verbal assent from o minor (7-12 yrs)alongWritten assent from o minor (13-18 yrs)with parental consentalong with parental consent
List of languages in which translation is done
Details of number of consent or/assent to be obtained in the study
 i.: Tick the included elements in the Consent form Understandable language Alternatives to participation Confidentiality of records
Sponsor of study Contact information
Purpose and procedures Image: Contact Information
Risks & Discomforts
Benefits Consent for future use of biological material
Compensation for participation Benefits if any on future commercialization
Compensation for study related injury eg. genetic basis for drug development
Translated in local language Need to recontact
*If written consent is not obtained, give reasons:
ii. Who will obtain consent ? PI/Co-PI
Research staff Any other
8. Payment/Compensation
Will you provide any form of payment/compensation to the participants Yes No
as a result of their participation?

9. Will any advertising be done for recruitment of Subjects? (posters, flyers, brochure, websites – if so kindly attach a copy) Yes No 10. Risks & Benefits: Image: social / psychological risk / discomfort? Yes No ii. Is there physical / social / psychological risk / discomfort? Yes No If Yes, Minimal or no risk More than minimum risk High risk Image: social / psychological risk / discomfort? Yes No In case if risks are involved, mention the risks and risk addressing mechanism: Image: social / psychological risk / discomfort? Yes No ii.Is there a potetial benefit ? Image: social / psychological risk / discomfort? Image: social / psychological risk / discomfort? Yes No ii.Is there a potetial benefit ? Image: social / psychological risk addressing mechanism: Image: social / psychological risk addressing mechanism: Image: social / psychological risk addressing mechanism: iii.Is there a potetial benefit ? Image: social / psychological risk addressing mechanism Image: social / psychological risk addressing mechanism: Image: social / psychological risk addressing mechanism: iii.Is there a potetial benefit ? Image: social / psychological risk addressing mechanism: Image: social / psychological risk addressing mechanism: b) to the society Image: social / psychological risk addressing mechanism: <	Ye yes, please give de	etails o	of the payment/co	mpensation			
ii. Is there physical / social / psychological risk / discomfort? Yes No If Yes, Minimal or no risk Image: Social / Psychological risk / discomfort? Yes No If Yes, Minimal or no risk Image: Social / Psychological risk / discomfort? Yes No If Yes, Minimal or no risk Image: Social / Psychological risk / discomfort? Yes No If Yes, Minimal or no risk Image: Social / Psychological risk / discomfort? Yes No In case if risks are involved, mention the risks and risk addressing mechanism: Risk Risk Risk Risk addressal mechanism Image: Social / Psychological risk / discomfort? Indirect benefit Image: Social / Psychological risk / discomfort? ii.Is there a potetial benefit ? No benefit Image: Direct benefit Image: Social / Psychological risk / discomfort? Indirect benefit Image: Social / Psychological risk / discomfort? b) to the society No benefit Image: Direct benefit Image: Image: Direct benefit Image: Image: Psychological risk / discomfort? Image: Psychological risk / discomfort? c) for improvement in knowledge No benefit Image: Direct benefit Image: Psychological risk / discomfort? Image: Psychological risk / discomfort?	•			0		Yes	No
If Yes, Minimal or no risk More than minimum risk High risk Image: Constraint of the second seco	10. Risks & Benefits:						
Risk Risk addressal mechanism ii.Is there a potetial benefit ? a) to the subject Indirect benefit Indirect b	If Yes, Minimal or no ri More than minir	isk		iscomfort?		Yes	No
Risk addressal mechanism ii.Is there a potetial benefit ? a) to the subject Indirect benefit Indirect bene	In case if risks are involved, mer	ntion th	ne risks and risk a	ddressing mechanism	:		
 ii.Is there a potetial benefit ? a) to the subject b) to the society c) for improvement in knowledge 	Risk						
 a) to the subject b) to the society c) for improvement in knowledge No benefit Direct benefit Direct benefit Direct benefit Direct benefit Indirect benefit	Risk addressal mechanism						
b) to the society Indirect benefit Indir	-	_					<u> </u>
c) for improvement in knowledge No benefit Direct benefit Indirect benefit	a) to the subject		No benefit	Direct benefit	Indi	rect be	nefit 🗖
	b) to the society		No benefit 🗖	Direct benefit 🔲	Ind	irect be	nefit 🗖
Montion the bonefits:		e 🗖	No benefit 🗖	Direct benefit 🗖	Ind	irect be	nefit 🗖
	Mention the benefits:						
Storage And Confidentiality	Storage And Confidentiality						
a) Identifying Information: Study Involves samples/data. If Yes, Specify	a) Identifying Information: Study	y Invol	lves samples/data.	If Yes, Specify			
Yes No NA	Yes 🛛 No 🖾 NA 🗖						
Anonymous/unidentified 🗖 Anonymized: reversibly coded 🗖 Irreversibly	Anonymous/unidentified 🗖 A	Anony	mized: reversibly	coded 🔲 Irrevers	ibly		
coded Identifiable	coded Identifiable						

If identifiers must be retained, what additional precautions will be taken to ensure		
that access is limited / data is safeguarded? (e.g. data stored in a cabinet, password		
protected computer etc.)		
b) Who will be maintaining the data pertaining to the study?		
c) Where will the data be analyzed and by whom?		
d) For how long will the data be stored?		
e) Do you propose to use stored samples/data in future studies? Yes No Maybe		
If yes, explain how you might use stored material/data in the future?		
SECTION D: OTHER ISSUES	X 7	NT
11. Data Monitoringi. Is there a data & safety monitoring committee/ Board	Yes	No
(DSMB)?		
ii. Is there a plan for reporting of adverse events?	Yes	No
If Yes, reporting is done to: Sponsor Ethics Committee DSMB		
iii. Is there a plan for interim analysis of	Yes	No
data?	105	NO
vi. Are there plans for storage and maintenance of all trial	Yes	No
database? If Yes, for how long?		
12. Is there compensation for participation?	Yes	No
If Yes, Monetary 🗖 In kind 🗖		
Specify amount and type:		
13. Is there compensation for injury?	Yes	No
If Yes, by Sponsor 🗖 by Investigator 🗖		
by insurance \Box by any other \Box		
company		

14. Do you have conflict of interest? (financial/nonfinancial) If Yes, specify :		Yes	No
SECTION E: CHECK LIST AND DECLARATIO	N		
Cover letter	Yes	No	NA
Copy of filled-in and duly signed IRB Form (4 copies)	Yes	No	NA
Project proposal – 4 Copies	Yes	No	NA
Short bio of the invigilators	Yes	No	NA
Curriculum Vitae of Investigators in prescribed format	Yes	No	NA
In case of collaborative research, attach the MOU with the collaborating organization	Yes	No	NA
Format of review type	Yes	No	NA
Participant information sheet-cum-Informed Consent form, (if multiple respondents, consent should be taken from each respondent)	Yes	No	NA
Informed Assent form (If applicable)	Yes	No	NA
Investigator self-declaration form	Yes	No	NA
Questionnaire and/or Copy of clinical trial protocol and/or interview guidelines	Yes	No	NA
Investigator's brochure for recruiting subjects	Yes	No	NA
Copy of advertisements/Information brochures	Yes	No	NA
Institutional Animal Ethics Committee clearance	Yes	No	NA
Any other specify	Yes	No	NA

CPCSEA clearance, if any	Yes	No	NA
HMSC/DCGI/DBT/BARC clearance if obtained	Yes	No	NA
Survey Protocol on COVID-related Measures	Yes	No	NA
		L	-

Date: Place: Principal Investigator